TG1N.F ARMATA PHARMACEUT.

Healthcare Biotechnology Frankfurt Exchange
3.34 EUR
Close of Nov 12, 2026
2.46 12.70
Market cap
EUR 124M
P/E
-
P/B
2.39x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.

Is TG1N.F undervalued?

Graham number

The Graham number of ARMATA PHARMACEUT. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ARMATA PHARMACEUT. fundamental analysis

No fundamental analysis for ARMATA PHARMACEUT. yet.

ARMATA PHARMACEUT. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ARMATA PHARMACEUT.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; and AP-PA03 for Pseudomonas aeruginosa. The company is based in Los Angeles, California. Armata Ph…

Full company profile